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Summary
Background: The characterization of an angiotensin-converting enzyme (ACE) in human pericardial fluid is relevant, 
considering its role in the angiotensin II release and thus, the role of the pericardium in cardiovascular homeostasis.
Objective: To isolate and characterize an ACE from human pericardial fluid and to compare the angiotensin I converting 
activities of the pericardial fluid with that of the serum in patients submitted to cardiovascular surgery.
Methods: The enzyme from human pericardial fluid was purified through chromatographic steps and characterized 
by polyacrylamide gel electrophoresis (SDS-PAGE), hydrolysis of angiotensin I, bradykinin, Hip-His-Leu and synthetic 
substrates with internal fluorescence suppression. Lisinopril was used as inhibitor. The ACE activity was measured in 
blood and pericardial fluid samples of 23 patients submitted to cardiovascular surgery. 
Results: The purified ACE (MM = 140 kDa), releases angiotensin II, hydrolyses bradykinin and the Hip-His-Leu 
substrate. The kinetic parameters kcat,(s-1) and kcat/Km (µM-1. s-1) were, respectively: Hip-His-Leu (1.14 and 7 x 10 -4) 
; Abz-YRK(Dnp)P-OH (2.60 and 0.77), Abz-LFK(Dnp)-OH (2.77 and 0.36) and Abz-SDK(Dnp)P-OH (1.92 and 0.19). The 
angiotensin I converting activities (mean ± SD) in the pericardial fluid and in blood, were, respectively: 3.16 ± 0.90 mU 
x mg –1x min-1 and 0.33 ± 0.11 mU x mg –1x min-1. The difference was significant between the two fluids.
Conclusion: An ACE that bears great similarity with the somatic enzyme was isolated from human pericardial fluid. 
The angiotensin I converting activity is higher in the pericardial fluid when compared to the serum activity. These 
data are important evidence of the role of the pericardial fluid in the metabolism of active peptides. (Arq Bras Cardiol 
2008;91(3):156-161)
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Introduction 
Studies with pericardial fluid have aimed chiefly at 
establishing the diagnosis of pericarditis, of pericardial effusion 
and have also been used for post-mortem diagnosis1-3. High 
levels of vasoactive and cardioprotective substances have 
been described in human pericardial fluid4,5. This fluid is in 
a strategic position to receive information concerning the 
pathologies that affect this space and the heart itself. Our 
interest regarding the biochemical study of the pericardial 
fluid aims at some enzymes, those that can function as local 
markers of physiopathological alterations. The present study 
was initiated with an isoform of the angiotensin-converting 
enzyme (ACE).
The angiotensin-converting enzyme (ACE) (EC 3.4.15.1) 
cleaves the angiotensin I, forming angiotensin II6 and hydrolyses 
bradykinin and kalidin, generating inactive fragments7. ACE 
is a membrane protein, described in arterial endothelium, 
epithelial and neuroepithelial tissues8-10. Several ACE isoforms 
are present in mammal tissues. A somatic isoform (150 – 180 
kDa), expressed in endothelial, epithelial and neuroepithelial 
cells has 2 homologous domains (N- and C- domains), each 
with its own catalytic site11,12. Another isoform with a lower 
molecular mass (90 – 110 kDa), found exclusively in male 
germinative cells, contain a single active site that corresponds 
to the C-domain of the somatic form13. 
Soluble forms of the enzyme are found in several body 
fluids, such as blood, amniotic fluid, semen, cerebrospinal 
fluid and urine14-16. A form constituted only of the N-domain 
was described in the ileal fluid17. Despite the high degree of 
homology, the C- and N-domains of the ACE differ in substrate 
specificity, inhibition profiles and chloride dependence18,19. 
The two active sites cleave angiotensin I, substance P and 
bradykinin with similar efficiency19. However, the natural 
tetrapeptide N-Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP)20 
and angiotensin 1-7 (Asp-Arg-Val-Tyr-Ile-His-Pro)21 are more 
specific for the catalytic N-domain. Peptides with internal 
fluorescence suppression [FRET (Fluorescence resonance 
energy transfer) peptides)], which contain sequences that 
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are susceptible to hydrolysis by ACE have been used for the 
characterization of N- and C-domains of the enzyme22-24.
The present work is the study of an ACE isoform, isolated for 
the first time from human pericardial fluid. We also compared 
the ACE activities in pericardial fluid and sera of individuals 
submitted to cardiovascular surgery in the present study. 
Methods
Reagents
Angiotensin I, angiotensin II, lisinopril, molecular mass 
patterns, bradykinin, o-phthalaldehyde, Hip-His-Leu, Mes (2-[N-
morpholino] ethanesulfonic Acid), HEPES ((N-(2-hydroxyethyl) 
piperazine-N’-(2-ethanesulphonic acid))]) were acquired from 
Sigma. The substrates with internal fluorescence suppression 
(FRET peptides), Abz-YRK(Dnp)P-OH, Abz-LFK(Dnp)-OH and 
Abz-SDK(Dnp)P-OH (Abz = o-aminobenzoic acid; Dnp = 2,4-
dinitrophenol) were synthesized at the Department of Biophysics 
of the Universidade Federal de São Paulo, São Paulo, SP, Brazil22-
24. Other reagents were obtained from Merck.
Obtaining the human pericardial fluid for the purification of 
the angiotensin-converting enzyme (ACE)
The pericardial fluid was collected up to 12 hours after 
death, from individuals without cardiac disease, during the 
necropsy performed at the Anatomopathological Department 
of the Universidade Federal do Triângulo Mineiro (UFTM), 
Uberaba, MG, Brazil. All samples used in the study were free 
of contamination with blood. 
Obtaining the human pericardial fluid and blood samples 
to measure the ACE activity 
Pericardial fluid and venous blood samples were collected 
from 23 patients submitted to cardiovascular surgery at Hospital 
de Clínicas of Universidade Federal do Triângulo Mineiro 
(UFTM), Uberaba, MG, Brazil. Pericardial fluid samples were 
obtained from the pericardial cavity by aspiration through a 
syringe, during the opening of the pericardial membrane for 
the heart surgery. The blood was obtained by venipuncture 
of the arm. 
The pericardial fluid and serum samples were centrifuged 
(1,000g, 15 minutes) and stored at -20oC. The pericardial fluid 
samples were free of contamination with blood. All patients 
gave their informed consent to participate in the study. All 
procedures were approved by the Ethics Committee in 
Research of UFTM (CEP/UFTM) and are in accordance with 
the Declaration of Helsinki. 
Purification of ACE from pericardial fluid 
Pericardial fluid (65 ml), free of visible contamination 
with blood or tissue and containing 1,550 mg of protein, 
was centrifuged at 3500 rpm, at 4oC. The supernatant was 
submitted to ultrafiltration (Amicon, YM-100) for a final volume 
of 20 ml containing 780 mg of protein. The concentrate was 
used for the purification of the angiotensin-converting enzyme, 
after dialysis against a 0.2 M sodium phosphate buffer, pH 
7.0. The protocol of purification included 3 chromatographic 
steps: 1) gel filtration through a Superdex 75 HR 10/30 
column, Pharmacia, balanced and eluted with a 0.05 M 
sodium phosphate buffer, containing 0.5M NaCl, pH of 6.5 
and flow of 1 ml per second. Aliquots of 0.5 ml were applied 
to the column and 1 ml fractions were collected; 2) affinity 
chromatography in a blue agarose (Cibacron) column, 
0.9 x 30 cm, (Bio Rad), balanced and eluted with a 0.2 M 
sodium phosphate buffer, pH 7.0 and flow of 0.5 ml/min. 
Aliquots of 2.0 ml were applied and fractions of 1 ml were 
collected; and 3) ion-exchange chromatography in a Mono Q 
5/5 HR column, Pharmacia, balanced with a 0.05 M sodium 
phosphate buffer, pH 6.5 and eluted by a NaCl gradient (0 to 
0.5 M) using a 0.05 M sodium phosphate buffer, pH 6.5 (buffer 
A) and 0.05 M sodium phosphate buffer, pH 6.5, containing 
0.5 M NaCl (buffer B). 
The flow was maintained at 1ml/min. Aliquots of 0.5 ml 
were collected. All chromatographic steps were monitored 
at 280 nm in a UV/VIS spectrophotometer (Pharmacia). 
The enzymatic activity of the fractions obtained at the 
chromatographic steps was tested using the Hip-His-Leu 
substrate, according to Friedland and Silverstein25. The 
presence of other proteins in the preparations obtained after 
each chromatographic step was verified through sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE -7.5%) under reducing conditions, as described by 
Laemmli26 (Bio-Rad system). Aliquots of the enzymatic 
preparations containing 2 to 10 µg of protein were applied 
to the gel. The gels were stained with ammoniacal silver27. 
Beta-amylase (200 kDa), bovine albumin (65 kDa), carbonic 
anhydrase (29 kDa) and lactalbumin (14 kDa) standards (all 
acquired from Sigma) were used to measure the molecular 
mass. The molecular mass was estimated through graphic 
interpolation. 
Enzymatic activity measurement 
Angiotensin I hydrolysis 
Angiotensin I (80 nmols) in a 0.1 M sodium phosphate 
buffer, pH of 7.5 (350 µl), containing 0.3 M NaCl, was 
incubated with ACE purified from pericardial fluid (4 ng 
in 10 µl) at 37oC. At 10 and 30 minutes of incubation, the 
aliquots were submitted to chromatography in an octadecyl 
silane column (C-18), balanced with acetonitrile:deionized 
water (1:5), containing 0.1% of Trifluoroacetic acid (TFA), 
coupled to a high-efficiency liquid chromatography (HPLC) 
system (Shimadzu). The elution was carried out using a 
gradient consisting of acetonitrile:deionized water (1:5), 
containing 0.1% TFA (buffer A) and acetonitrile containing 
0.1% TFA (buffer B). The peptides were monitored at 214 nm 
through a UV/VIS spectrophotometer and identified through 
the retention time using angiotensin I and angiotensin II as 
standards. The peak that corresponded to the angiotensin II 
standard was tested using a biological assay in isolated rat 
uterus28. The biological activity was estimated using solutions 
with known concentrations of angiotensin I and angiotensin 
II as standards. The assays that used animals were developed 
according to the directives established by the “Guide for Care 
and Use of Laboratory Animals” (Institute of Laboratory Animal 
Resources, National Academy of Sciences, Washington, DC) 
and the Ethical Principles in Animal Experimentation of the 
Brazilian College of Animal Experimentation (COBEA). 
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Bradykinin hydrolysis 
Bradykinin (BK, 5 nmols) was incubated with the converting 
enzyme purified from pericardial fluid (4 ng), in a 0.2 M 
phosphate buffer, pH 7.5 containing 0.3 M NaCl, for a final 
volume of 300 µl, at 37oC, during 10 minutes and tested using a 
biological assay in isolated rat uterus28. A BK standard (5 nmols) 
was incubated under the same conditions, in the absence of 
the enzyme and used as control. A BK dose-response curve 
was used to quantitatively assess the biological activity of the 
aforementioned incubation mixes. The disappearance of 
the biological activity of the BK was considered as kininasic 
activity. Inhibition assays were performed using Na2EDTA (40 
mM) and lisinopril (2.5 µM).
Kinetic studies 
Hydrolysis of the hip-his-leu substrate 
The establishment of the optimal pH for the hydrolysis of 
the Hip-His-Leu substrate was performed using the following 
buffers: 0.2 M glycine-HCl (pH 3.0 to 4.0), 0.2 M sodium 
acetate (pH 4.5 to 5.5), 0.2 M sodium phosphate (pH 6.0 to 
7.5), 0.2 M Tris-HCl (pH 8.0 to 8.5) and 0.2 M glycine-NaOH 
(pH 9.0), containing 0.3 M NaCl, for a final volume of 490 
µL, and the purified enzyme (4 ng). The assay was carried 
out as proposed by Friedland and Silverstein25. The kinetic 
parameters (kcat and Km) for the hydrolysis of the Hip-His-Leu 
substrate (0.25 – 3 mM) were determined using the purified 
enzyme (4 ng) in a 0.1 M potassium phosphate buffer, pH 
8.3, containing 0.3 M NaCl, for a final volume of 490 µl. 
The mix was incubated at 37oC for 15 minutes. The reaction 
was interrupted by the addition of 1.2 ml of 0.34 M NaOH, 
followed by the addition of 200 µL of 3M HCl, and the His-
Leu dipeptide was quantified fluorimetrically (Exc.365 nm; 
Em.495 nm) through the formation of a fluorescent product 
with 100 µl of a solution of 150 mM o-phthalaldehyde. The 
results were expressed as nmol x ml-1 x min-1. Lisinopril (2.5 
µM) was used for the inhibition experiments. 
Hydrolysis of Abz-YRK(Dnp)P-OH, Abz-LFK(Dnp)-OH and 
Abz-SDK(Dnp)P-OH
The assays with substrates that had internal fluorescence 
suppression were carried out as previously described22-24. 
The optimal pH was determined using aliquots (4 ng) of the 
purified enzyme and a buffer solution containing: 25 mM of 
glycine, 25 mM of acetic acid, 25 mM of Mes and 75 mM 
of Tris in the presence of 100 mM of NaCl and 10 µM of 
ZnCl2 in a pH range of 5.0 to 9.5, for a final volume of 1 ml, 
at 37oC. The kinetic parameters were determined at 37oC, 
in 0.1 M Tris-HCl buffer (pH 7.0) containing NaCl (0.05 M), 
ZnCl2 (10 µM) and the substrates Abz-YRK(Dnp)P-OH, Abz-
LFK(Dnp)-OH and Abz-SDK(Dnp)P-OH. The enzymatic activity 
was continuously monitored through a fluorometer (Hitachi 
F-2000) and the fluorescence was measured at 420 nm (λem) 
after stimulation at 320 nm (λexc). The concentration of the 
enzyme to determine the initial velocity of the reaction was 
chosen so that the hydrolysis was not higher than 5% of the 
used substrate. The fluorescence variation was converted in 
micromoles of hydrolyzed substrate per minute, based on a 
calibration curve obtained after the complete hydrolysis of 
each peptide. The values of kcat/Km were calculated based 
on the kinetic parameters kcat and Km, obtained through 
the analysis of linear regression of the data with the GraFit 
program29. The standard deviations for kcat and Km were lower 
than 7%. The hydrolysis inhibition was carried out using 
lisinopril (2.5 µM).
Influence of chlorides on catalytic activity 
The influence of chloride ions (0 – 500 nM) on the catalytic 
activity of the enzyme isolated from human pericardial fluid 
was investigated using the substrate Abz- YRK(Dnp)P-OH (10 
µM) at 37oC in 1 ml of 50 mM HEPES buffer (pH 7.6) containing 
ZnCl2 (10 µM) and 4 ng of the enzyme. The hydrolysis was 
fluorimetrically monitored as previously described22.
Angiotensin converting activity in serum and pericardial 
fluid 
The angiotensin I-converting activities in serum and 
pericardial fluid were measured using Abz-YRK(Dnp)P-
OH (10 µM) – substrate for the N and C-domains of 
the enzyme at 37oC in a 0.1 M Tris-HCl buffer (pH 7,6) 
containing 0.05 M NaCl and 10 µM ZnCl2. One hundred 
µL of the pericardial fluid and serum samples were added 
to the substrate solution for a final volume of 2.0 ml and 
the enzymatic activity was monitored fluorimetrically as 
previously described22. A fluorescence curve was obtained 
using the peptide standards before and after total hydrolysis. 
The enzymatic activity was expressed as milliunit per 
milligram of protein per minute of incubation (mU × mg-
1 × min-1). The measurements were made in duplicate. 
The hydrolytic activity of the enzyme was totally inhibited 
by 2.5 µM lisinopril. The data were analyzed through non-
paired Student’s t test with a level of significance set at 0.05. 
The protein concentrations in serum and pericardial fluid 
were measured by the biuret method30. A standard protein 
solution was used in the same conditions of the samples 
and the results were expressed as mg x ml-1. 
Results
Pericardial fluid ACE purification
An angiotensin-converting enzyme was purified up to 
homogeneity from human pericardial fluid using YM-100 
membrane filtration to eliminate proteins with molecular 
masses < 100 kDa followed by three chromatographic 
phases and among them, an affinity chromatography phase 
(Cibacron blue agarose) with the objective of removing the 
residual albumin still present in the concentrate. The enzyme 
was purified around 300 times. The protocol used resulted in 
200 µg of purified protein, with specific activity of 3,975 nmol 
His-Leu x mg-1 x min. The SDS-PAGE yielded a single protein 
band under reducing conditions, with apparent molecular 
mass of 140 kDa (Figure 1). 
The purified enzyme converts angiotensin I into angiotensin 
II as demonstrated by the reverse-phase chromatographic 
analysis (C18-CLAE) (Figure 2) and by the biological activity 
on the isolated rat uterus (Figure 3). 
The kininasic activity of the enzyme was demonstrated 
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Figure 1 - Sodium dodecyl sulfate Polyacrylamide Gel Electrophoresis, SDS-
PAGE (7.5% of cross-binding), under reducing conditions, of ACE isolated 
from human pericardial fluid. Slot 1 – ACE from pericardial fluid (5 µg); Slot 2 
– molecular mass standards (beta-amylase = 200 kDa; bovine albumin = 65 
kDa; carbonic anhydrase = 29 kDa; lactalbumin = 14 kDa)
Figure 2 - High-efficiency liquid chromatography - HELC (Reverse Phase 
– C18) of the incubation mixture of ACE of human pericardial fluid and of 
Angiotensin-I (80 mmols) in 0.1 M sodium phosphate buffer, pH 7.5, containing 
0.3 M NaCl, during 10 minutes (a) and 30 minutes (b); The mixture was applied 
to a LiChrospher column RP-18 (4.6 x 125 mm, Merck), equilibrated with 20% 
acetonitrile in water, containing 0.1% of trifluoracetic acid (0.1%) (solvent A) 
and eluted with 100% acetonitrile containing 0.1% of trifluoracetic acid (0.1%) 
(solvent B) and flow = 1 ml/min. A 0% to 80% linear gradient of buffer B was 

















Figure 3 – B����g���� ������ �n �������d ��� u���u�� Ang����n��n II ����m����n ������ 
incubation with ACE of human pericardial fluid with angiotensin I. (a) angiotensin 
I (80 nmols in 350 µl of 0.1 M sodium phosphate buffer, pH 7.5, containing 0.3 M 
NaCl, incubated for 10 minutes, at 37oC); (b) angiotensin II (80 nmols – in 350 µl 
of 0.1 M sodium phosphate buffer, pH 7.5, incubated for 10 minutes, at 37oC); (c) 
angiotensin I (80 nmols) and ACE ECA from human pericardial fluid (4 ng) in 350 
µl 0.1 M sodium phosphate buffer, pH 7.5, at 37oC, incubated for 10 minutes; (d) 
angiotensin I (80 nmols) and ACE from human pericardial fluid (4 ng) in 350 µl 0.1 











through the disappearance of the biological activity of 
bradykinin on the isolated rat uterus, after incubation with the 
purified enzyme (Figure 4). All the hydrolytic activities shown 
by the enzyme were totally inhibited by lisinopril.
Figure 4 – B����g���� ������ �n �������d ��� u���u�� ACE k�n�n���� ��������� ��� �um�n 
pericardial fluid using bradykinin as substrate. (a) Bradykinin pattern (BK) – 5 nmols 
in 0.2 M sodium phosphate buffer, pH 7.5, containing 0.3 M NaCl; (b) Control – BK - 5 
nmols in 0.2 M sodium phosphate buffer, pH 7.5, containing 0.3 M NaCl, incubated at 
37oC for 10 minutes; (c) Test – BK - 5 nmols in 0.2 M sodium phosphate buffer, pH 
















(μM��x s��)-1  -1
Hip-His-Leu 1.14 1654 7 x 10-4
Abz-YRK(Dnp)P-OH 2.60 3.4 0.77
Abz-LFK(Dnp)-OH 2.77 7.7 0.36
Abz-SDK(Dnp)P-OH 1.92 10.2 0.19
Assay’s conditions: The hydrolyses of the substrates with fluorescence 
suppression by ACE of the human pericardial fluid were performed at 37�C, 
pH 7.6 (100 mM Tris-HCl buffer, containing ZnCl2,10 µM). The enzymatic 
activity was continuously followed by measuring fluorescence at 420 nm 
(λ�m) after stimulation at 320 nm (λ���). The kinetic parameters of purified 
ACE (k��� and Km), for the hydrolysis of the Hip-His-Leu substrate (0.25 
– 3mM), were measured at pH 8.3 (0.1 M potassium phosphate buffer, 
containing 0.3 M NaCl), at 37�C, using 4 ng of the purified enzyme. The 
His-Leu dipeptide was quantified fluorimetrically (Exc.365 nm; Em. 495nm) 
������ ��� �dd����n ��� �-��������d����d��
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Table 2 – Angiotensin-I con�erting acti�ity and �rotein content in 









�U x �g –1x �in-1
Mean
(n = 23) 20.6# 3.16* 61.7 0.33
SD 5.6 0.90 8.3 0.11
Assay’s conditions: ACE activity in pericardial fluid and serum samples of 
�����n�� �u�m����d �� ���d������u��� �u�g���� w�� m���u��d u��ng ��� A�z-
YRK(Dnp)P-OH (10 µM) substrate at 37�C , in 0.1 M Tris-HCl buffer (pH 
7.0) containing 0.05 M of NaCl and 10 µM of ZnCl, in a final volume of 2.0 
ml. Abz = o-aminobenzoic acid; DNP = 2,4-Dinitrophenol. The assays were 
�������m�d �n du�������� P�����n ��n��n� w�� m���u��d ��� ��� ��u��� m����d� 
SD= standard deviation; *p < 0.05, #p < 0.05, compared with serum.
The effect of pH on the hydrolysis of the fluorescent 
substrate AbzYRK(Dnp)P-OH showed better hydrolytic activity 
at pH 7.65. The curve obtained is similar to the hydrolysis 
profile of the native enzyme for several substrates. 
The effect of the concentration of NaCl on the hydrolysis 
of the substrate Abz-YRK(Dnp)P-OH was determined to assess 
the C-domain activation by the chloride ions. The maximum 
activity was observed with 100 mM NaCl and maintained at 
the same level up to 500 mM.
The angiotensin-converting activity in the patients’ serum 
and pericardial fluid is shown in Table 2. The data analysis 
showed a significant difference between the two fluids. 
Regarding the protein content of the pericardial fluid, a ratio 
was maintained, which varied from 1/2 to 1/3 compared to 
the plasma. Therefore, the enzymatic activity was expressed 
as specific activity (mU x mg-1 x min-1).
Discussion and Conclusion
The present study isolated and characterized, for the 
first time, an angiotensin-converting enzyme from human 
pericardial fluid. The molecular mass (140 kDa) obtained 
through polyacrylamide gel electrophoresis for the isolated 
isoform, showed to be different when compared to 
literature data, where molecular masses of 90-110 and 150-
180 kDa are described12–14. This difference could be due 
to the post-translational modifications, such as polypeptide 
chain cleavages and/or glycosylation in the isoform of the 
pericardial fluid. 
 Our data show that the enzyme hydrolyses the classic 
substrate for the angiotensin-I converting enzyme, Hip-His-
Leu, cleaves the Phe-His bond in angiotensin I generating 
angiotensin II and has kininase activity, hydrolyzing bradykinin 
to inactive products. 
 These observations indicate that the enzyme isolated 
here bears great hydrolytic similarity to the somatic enzyme. 
With the objective of better characterizing the enzyme from 
human pericardial fluid, assays with synthetic substrates 
susceptible to hydrolysis by the C- and N-domains of 
ACE were used and the results obtained showed that the 
isolated isoform presents the two active sites, similar to the 
somatic ACE. The effect of the chloride ions on the catalytic 
activity showed an activation profile that was very similar 
to the native isoform23. Regarding the catalytic constants 
obtained for the purified enzyme using the several synthetic 
substrates, we observed data for Km, that were similar 
to those found for the recombinant form. However, the 
data obtained for kcat/Km showed that the enzyme of the 
pericardial fluid presented less catalytic efficiency than the 
recombinant form23. 
The inhibition of all hydrolytic activities that were tested 
using lisinopril reinforced the nature of the angiotensin-
converting enzyme of the isoform isolated here. 
Our findings are even more relevant considering that they 
concern human pericardial fluid, as it is known that in vitro 
studies performed in the myocardium of different species 
showed that ACE constitutes the main angiotensin-II forming 
pathway, with the human heart, as well as the hamster and 
dog hearts, being the exception to this rule. Therefore, great 
caution must be exercised when extending to the human 
heart, data collected from other species31. 
 The endothelium has been considered the main source 
of ACE in the normal heart32,33. However, experimental 
studies have shown a strong ACE labeling in fibrosed visceral 
pericardium, in post-infarction myocardium as well as in the 
control group, where only the opening of the pericardial 
membrane was performed, suggesting that the fibrosed 
heart tissue can be a source of angiotensin-II34.
The possibility of synthesis and secretion of macromolecules 
through the mesothelial layer of the pericardium can 
be supported by the data obtained by Ishihara et al35, 
who observed intercellular junctions between adjacent 
mesothelial cells, which constitute a barrier to the free 
diffusion of macromolecules between the blood and the 
pericardial cavity36.
Using the same substrate susceptible to the C-and N-
domains of ACE, used to characterize the isoform that was 
isolated in this study, we performed a comparative study 
to determine the angiotensin-I converting activity in the 
pericardial fluid and plasma, showing that the activity in 
the pericardial fluid is higher than that in plasma. 
This corroborates the hypothesis of a local-origin 
isoform, with hydrolytic properties that are similar to the 
plasma ACE, which does not exclude the possibility of 
the presence of other isoforms. The pericardial fluid is a 
plasma ultrafiltrate through the myocardium and it is very 
unlikely that the isoform isolated in our study has plasmatic 
origin, as the process of diffusion is limited to molecules 
with molecular masses < 40 kDa. It is more probable 
that it originates from cells inside the pericardium or the 
mesothelial layer.
Therefore, one cannot consider the pericardium a 
mere container that has a small amount of lubricating 
fluid inside. 
The presence of the angiotensin-I converting enzyme in the 
pericardial fluid-myocardium interface constitutes important 
evidence of the role of the pericardium in the regulation of 
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the cardiovascular homeostasis. It is possible that part of the 
effects of the angiotensin-II on the heart is a consequence of 
its pericardial production. 
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